Rocket


Overview
Financials
News + Filings
Key Docs
Transactions
Holdings
Ownership


All
13F
13D/G
Other

Cellectis S.A. (CLLS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 6-K Quarterly results
09/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer 38th Annual Meeting NEW YORK, Sept. 27, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 38 th Annual Meeting , that will take place on November 1-5, 2023 at San Diego Convention Center in San Diego . Poster Presentation:"
08/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis Provides Full Report for Second Quarter 2023 Financial Results NEW YORK, Aug. 07, 2023 -- Cellectis S.A. , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the release of the full report of the financial results for the second quarter 2023 and filing of the corresponding 6-K with the SEC. Financial Results The interim condensed consolidated financial statements of Cellectis, have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board . We present certain financial metrics broken out between our two reportable segments – Therapeutics and Plants – in the appendices of this Q2 2023 financial results press re..."
08/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cellectis S.A.'s interim report for the six-month period ended June 30, 2023"
08/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023"
07/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023 NEW YORK, July 27, 2023 -- Cellectis S.A. , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 after the close of the US market. The announcement will be followed by an investor conference call and webcast on Friday, August 4, 2023 at 8:00 am ET / 2:00 pm CET. The call will include the Company’s second quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: 1-877-451-6152 International: 1-201-389-0879 Conference ID: 13739252 Webcast Link: https://via..."
07/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors NEW YORK, July 12, 2023 -- Cellectis S.A. , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that during the annual shareholders meeting held on June 27, 2023, Cécile Chartier, Ph.D., has been appointed as a Director of the Company’s Board of Directors, with immediate effect. “We are very excited to welcome Dr. Chartier as a director of Cellectis’ Board of Directors. Cécile’s extensive experience in the development of next generation cell and gene therapies coupled with her deep knowledge of the U.S. biotechnology industry will be a huge asset to the Company,” said André Choulika, Ph.D., Chief Executive Officer at Cellectis..."
06/29/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 27, 2023 June 28, 2023 - New York - Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which more than 72% of shares were exercised, Resolutions 1 through 28 were adopted and resolution 29 was rejected, according to the management recommendations. The detailed results of the vote and the resolutions are available on the company's website: https://www.cellectis.com/en/investors/general-meetings/ About Cellectis Cellectis is a clinical-stage biotechnology comp...",
"Against Vote withhold Total votes Sharesrepresentedby thevotes cast Percentage of theshare capitalrepresented by thevotes cast Out of votevotingrights Null votingrights Quorum Votes % Votes % Votes % 1 Approval of the annual financial statements for the financial year ended December 31, 2022 1 Carried 44 957 162 99.48 % 233 303 0.52 % 27 732 — 45 190 465 40 379 160 72.645 % 0 0 72.645 % 2 Approval of the consolidated financial statements for the financial year ended December 31, 2022 2 Carried 44 957 137 99.48 % 233 303 0.52 % 27 757 — 45 190 440 40 379 160 72.645 % 0 0 72.645 % 3 Appropriation of results for the financial year ended December 31, 2022 3 Carried 44 926 569 99.41 % 265 543 0.59 % 26 085 — 45 192 112 40 379 160 72.645 % 0 0 72.645 % 4 Allocation of losses carried forward to t..."
06/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023 NEW YORK, June 28, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which more than 72% of shares were exercised, Resolutions 1 through 28 were adopted and resolution 29 was rejected, according to the management recommendations. The detailed results of the vote and the resolutions are available on the company’s website: https://www.cellectis.com/en/investors/general-meetings/ About Cellectis Cellectis is a clinical-stage biotechnology comp..."
06/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association 2023 NEW YORK, June 09, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated clinical and translational data on its clinical trial BALLI-01 at the European Hematology Association 2023. The data presented support the preliminary safety and efficacy of UCART22 in a heavily pretreated relapsed/refractory B-cell acute lymphoblastic leukemia population. “These clinical data are very positive for patients with r/r B-ALL who have failed multiple lines of treatment options including chemotherapy, CD19 directed CAR T-cell therapy and allogeneic stem cell transplant and en..."
05/31/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies"
05/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023 NEW YORK, May 17, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data on its Phase 1 AMELI-01 clinical trial that were unveiled in an oral presentation at the 64 th American Society of Hematology annual meeting, as well as preclinical data on multiplex engineering for superior generation of CAR T-cells, at the American Society of Gene and Cell Therapy 2023 Annual Meeting. Oral presentation: AMELI-01, a study evaluating UCART123, an allogeneic CAR T-cell product candidate, in relapsed/refractory acute myeloid leukemia The or..."
05/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors NEW YORK, May 12, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Frontiers Bioenginnering, demonstrating the efficacy of its TALEN® engineered FAP UCART-cells in cancer-associated fibroblast depletion, reduction of desmoplasia and tumor infiltration. Adoptive cell therapy based on chimeric antigen receptor-engineered T cells has proven to be lifesaving for many cancer patients. However, its therapeutic efficacy has so far been restricted to only a few malignancies, with solid tumor..."
05/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association 2023 BALLI-01 abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL population NEW YORK, May 11, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the release of an abstract, which was accepted for presentation at the European Hematology Association Hybrid Congress, taking place on June 8-15, 2023 in Frankfurt, Germany. Cellectis will present, in a poster session, updated clinical and translational data on its BALLI-01 clinical trial in patients with relapsed/refractory B-cell acute lymphoblastic Leukemia . “Cellectis is excited to present upda..."
05/04/2023 6-K Quarterly results
05/02/2023 6-K Quarterly results
04/27/2023 6-K Quarterly results
04/24/2023 6-K Quarterly results
04/17/2023 6-K Quarterly results
04/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million - April 4, 2023 - Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies today announced that the Company entered into the warrant agreement and finalized the related ancillary documents required under the credit facility with the European Investment Bank for up to €40 million previously announced on December 28, 2022. The Company also announced the drawdown of the first tranche of €20 million under the Finance Contract, expected to be disbursed by the EIB in early April 2023. The Company plans to use the proceeds of Tranche A toward..."
03/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research Annual Meeting NEW YORK, March 14, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preclinical data exploring purposeful armoring of CAR T-cells to enhance efficacy of MUC1 CAR T-cells in targeting triple-negative breast cancer, will be presented at the American Association of Cancer Research Annual Meeting, to be held in Orlando, Florida on April 14-19, 2023. “We are proud to present updated preclinical data on our product candidate UCARTMUC1 for solid tumors at AACR 2023,” said Laurent Poirot, Ph.D., Senior V..."
03/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results"
03/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CALYXT, INC. CONSOLIDATED BALANCE SHEETS December 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 3,427 $ 13,823 Restricted cash 99 499 Prepaid expenses and other current assets 606 859 Total current assets 4,132 15,181 Non-current restricted cash — 99 Land, buildings, and equipment 4,516 21,731 Operating lease right-of-use assets 13,615 — Other non-current assets 158 183 Total assets $ 22,421 $ 37,194 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 340 $ 1,260 Accrued expenses 173 339 Accrued compensation 107 2,522 Due to related parties 175 172 Current portion of financing lease obligations 97 370 Common stock warrants 291 — Other current liabilities 479 191 Total current liabilities 1,662 4,854 Financing lease obligations — 17,5..."
03/01/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023 NEW YORK, March 01, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and year-end 2022 ending December 31st , 2022, on Wednesday, March 8, 2023, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Thursday, March 9, 2023, at 8:00 AM ET / 2:00 PM CET. The call will include the Company’s fourth quarter results, year-end results, and an update on business activities. Details for the call are as follows: Dial-in information: Domestic: 1-877-451-6152 International: 1-201-..."
02/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opinion of Jones Day, French counsel to the registrant"
02/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Underwriting Agreement, by and between Cellectis S.A. and Jefferies LLC and Barclays Capital Inc., as representatives of the underwriters",
"Opinion of Jones Day, French counsel to the registrant"
02/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Investor Relations contacts: Arthur Stril, Chief Business Officer, +1 809 5980, [email protected] Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577 Disclaimers"
02/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Investor Relations contacts: Arthur Stril, Chief Business Officer, +1 809 5980, [email protected] Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577 Disclaimers"
02/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Investor Relations contacts: Arthur Stril, Chief Business Officer, +1 809 5980, [email protected] Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577 Disclaimers"
01/20/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Attachment"
01/17/2023 6-K Quarterly results
01/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement NEW YORK, Jan. 17, 2023 -- Cellectis , a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and gene therapies, announced today that Cibus Global LLC, a Delaware limited liability company , and Calyxt, Inc. , announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein , pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. The transaction combines two companies in agriculture-based gene editing, with facilities for trait development and next-..."
01/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cellectis S.A. Media contacts: Pascalyne Wilson, Director, Communications, +33 7 76 99 14 33, [email protected] Margaret Gandolfo, Senior Manager, Communications +1 628 0300, [email protected] Arthur Stril, Chief Business Officer, +1 809 5980, [email protected] Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577 Disclaimers"
01/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Opinion of Jones Day",
"First Amendment to the Sales Agreement, by and between Cellectis S.A. and Jefferies LLC",
"Opinion of Jones Day"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy